NewLimit: Adding healthy years to each human life

Throughout history, humans have sought to extend not just lifespan, but the quality of life itself. Once thought to be irreversible, the emerging science of epigenetic reprogramming has shown that aging is, in fact, malleable.

NewLimit was founded with an audacious mission – to radically extend human health-span, by developing medicines that add healthy years to each human life. Rather than targeting narrow disease, their incredible team, led by Brian Armstrong, Blake Byers, Jacob Kimmel, and Cathy O’Hare, is working toward treating aging that affects us all, presenting a therapeutic opportunity 100X larger than ever before.

NewLimit’s approach is conceptually straightforward and deeply technical. They run the largest experiments in the field, and use the resulting data to train frontier AI models. This combination of AI and scaled genomics can unlock medicines that give each of us more healthy years.

While merely a dream at the Series A, the NewLimit team has executed on this vision and demonstrated incredible early results. They’ve built computational and lab infrastructure and scaled experiments 50x in one year. They’ve built the first AI models that explain more than half of reprogramming outcomes, so that only the best ideas are tested in the lab.

With these foundations in place, NewLimit has tested 600 times more reprogramming medicines in three years than the rest of the field combined. This has led to the discovery of 100+ reprogramming payloads that make old human cells look young, and the discovery of three prototype medicines that treat animal models of liver disease. And they’ve done all this with a lean and deeply technical team where everyone runs experiments, writes code, or moves atoms.

NewLimit is making their mission a reality and we’re excited to double-down on our partnership and lead their Series B. If you’re interested in joining the journey, they’re hiring.

— ilya